ArticleMolecular pharmaceutics2013

Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.

Geoffrey D Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.